IP Library › Granted Patent US 11,058,729
Granted Patent B2
US 11,058,729 · App. 16/257,026 · Granted Jul 13, 2021

Exosomes and miRNA to treat glaucoma

Inventors: Stanislav Ivanovich Tomarev (Kensington, MD); Benjamin Frank John Martin Mead (Silver Spring, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
A61K35/28A61K9/0019A61K9/0048A61P27/10C12N5/0663C12N15/113A61K45/06C12N2310/14C12N2310/141
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,058,729
App. No.
16/257,026
Granted
Jul 13, 2021
Kind
B2
Abstract

Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed method use exosomes and/or miRNA.

Claims (16)

1. A method for treating glaucoma in a subject, comprising:

selecting a subject with glaucoma, and

locally administering to an eye of the subject a therapeutically effective amount of exosomes from mesenchymal stem cells, thereby treating the glaucoma in the subject.

2. The method of claim 1 , wherein the exosomes are from human mesenchymal stem cells, and wherein the subject is human.

3. The method of claim 1 , wherein the mesenchymal stem cells were treated with a priming agent.

4. The method of claim 3 , wherein the priming agent is tumor necrosis factor (TNF)-α.

5. The method of claim 1 , wherein the exosomes are from bone marrow derived mesenchymal stem cells, umbilical cord blood derived mesenchymal stem cells, adipose tissue derived mesenchymal stem cells, or dental pulp stem cells.

6. The method of claim 1 , wherein the exosomes are CD11c + and CD63 + .

7. The method of claim 1 , wherein the exosomes are administered intravitreally to the eye of the subject.

8. The method of claim 1 , wherein the mesenchymal stem cell exosomes are administered repeatedly to the eye of the subject.

9. The method of claim 8 , wherein the mesenchymal stem cell exosomes are administered weekly, bi-monthly or monthly to the subject.

10. The method of claim 1 , wherein the administration of the exosomes increases retina ganglion cell survival in the eye of the subject.

11. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an agent that lowers intraocular pressure,

wherein the agent that lowers intraocular pressure is a) a prostaglandin analog, b) a beta-adrenergic blocker, c) an alpha-adrenergic agonist, or d) a cholinergic agonist.

12. The method of claim 11 , wherein the agent that lowers intraocular pressure is a) latanoprost, b) timolol, c) brimonidine, or d) pilocarpine.

13. The method of claim 1 , wherein the exosomes are from a) bone marrow derived mesenchymal stem cells; and b) CD11c + and CD63 + .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2019
From: TOMAREV, STANISLAV IVANOVICH; MEAD, BENJAMIN FRANK JOHN MARTIN
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 048514/0705 →
Continuity (2)
Provisional Application 62622032 · Jan 25, 2018
Related Publication 20190224242A1 · Jul 25, 2019
Cited By (5)
US 12,274,733 US 12,409,207 US 12,414,982 US 12,582,698 US 12,624,362